Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μMIn VitroGardiquimod diTFA (6-60 μM ) significantly inhibits cDNA synthesis by HIV-1 reverse transcriptase. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoDendritic cells (DCs) in combination with Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) improves the anti-tumor effects of NK cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male athymic nude mice (Balb-nu/nu, 5 weeks old) (bearing human HepG2 liver carcinoma xenografts)Dosage: 1 mg/kg per mouse Administration: i.p.; daily for 7 days Result: Significantly suppressed the growth of human HepG2 liver carcinoma xenografts.IC50& Target:TLR7 TLR8 HIV-1. Specification: 10mM in DMSO Molecular Formula: C21H25F6N5O5 Molecular Weight: 541.4
- UPC:
- 51343300
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- G655140-1ml
- CAS:
- 1159840-61-5
- Product Size:
- 1ml
